Published in final edited form as:

AIDS Behav. 2019 March ; 23(3): 564–571. doi:10.1007/s10461-018-2273-4.

Depressive symptoms before and after antiretroviral therapy initiation among older-aged individuals in rural Uganda

Jennifer Manne-Goehler^{1,2}, Bernard Kakuhikire³, Sheilah Abasabyoona³, Till W. Bärnighausen^{2,4}, Samson Okello³, Alexander C. Tsai^{3,5,6}, Mark J. Siedner^{3,6,7}

¹Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; ²Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA; ³Mbarara University of Science and Technology, Mbarara, Uganda; ⁴Institute of Public Health, University of Heidelberg, Heidelberg, Germany; ⁵Chester M. Pierce, MD Division of Global Psychiatry, Massachusetts General Hospital, Boston, MA; ⁶Massachusetts General Hospital Center for Global Health, Harvard Medical School, Boston, MA ⁷Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA

Abstract

BACKGROUND: This study aims to characterize associations between depression symptom severity and HIV infection, both prior to and years after ART initiation.

METHODS: The Ugandan Non-Communicable Diseases & Aging Cohort Study (UGANDAC) is a study of 154 PLWH on ART and 142 community-based, HIV-negative controls. The Hopkins Checklist (HSCL), a 15-item depression scale, was used to screen for depression. We estimate differences in depressive symptoms by HIV and ART status and used multivariable log binomial regression to quantify differences in probable depression between PLWH on ART.

FINDINGS: HIV-infected and HIV-uninfected participants had similar age (mean 52.0 v. 51.9, $p=0.854$) and sex distribution (47.4 v. 47.9% female, $p=0.934$). PLWH on ART had lower depression symptom severity than HIV-uninfected controls (mean score: 1.50 v. 1.60, $p=0.006$) and a lower prevalence of probable depression (21.4 versus 33.8%, $p=0.017$). Among 102 PLWH with pre-ART depression screening scores available, their mean depression symptom severity was similar to HIV-uninfected participants (mean 1.56 v. 1.60, $p=0.512$). In adjusted models, PLWH on ART had a lower prevalence of probable depression than HIV-negative controls [adjusted prevalence ratio: 0.68 (95% CI: 0.47 – 0.99)].

CONCLUSIONS: Our findings add to a growing body of literature demonstrating improved health indicators among PLWH on ART in sub-Saharan Africa, compared to people without HIV.

Keywords

depression; antiretroviral therapy

In the era of widespread availability of antiretroviral therapy (ART), HIV-positive people are living to older ages in sub-Saharan Africa.¹ There is a growing recognition of the role of mental health conditions as an important source of comorbidity among people living with HIV (PLWH).² For instance, a recent meta-analysis of PLWH, including both those prior to and on ART, estimated a pooled prevalence of depression ranged between 9% and 32%, with substantial variability across geographic contexts, and measurement approaches.^{3,4}

Depression and other mental health disorders have complex and potentially far reaching implications for health and well-being, including risk of disease acquisition and engagement in care for chronic conditions such as HIV.^{5,6} The relationship between depression and engagement in HIV care has been demonstrated in several low- and middle-income settings.^{7,8} In PLWH, depressive symptoms are an important barrier to HIV self-care and adherence to ART.^{7,9,10} In a large systematic review of studies from across sub-Saharan Africa, depression was significantly associated with ART non-adherence (OR 2.54, 95% CI 1.65 – 3.91).⁶ In a second multi-country study, over 2,400 participants across 6 countries in sub-Saharan Africa reported depression as a barrier to ART adherence.¹¹ These findings are likely related to both biological and social determinants of depression among PLWH, as HIV remains heavily stigmatized throughout sub-Saharan Africa and the stigma attached to HIV remains a significant structural barrier to treatment adherence.^{12–14} Given these findings, the ability to diagnose and treat depression may be an important element in efforts to improve adherence and outcomes for HIV or other chronic diseases.

Depression has also been linked to a number of deleterious health behaviors in low- and middle-income countries (LMICs).¹⁵ A study in South Africa showed that symptoms of depression at baseline were associated with increased risk of high-risk sexual behavior, including transactional sex in both men (aOR = 1.48, 95% CI 1.01–2.17) and women (aOR = 2.60, 95% CI 1.37, 4.92) and lower odds of correct condom use at last sex (aOR = 0.50, 95% CI 0.32–0.78).¹⁶ A similar study in Uganda also demonstrated a relationship between depression and high-risk sexual behavior in women and several studies have shown relationships between depression, alcohol or other substance use and high-risk sexual behavior in sub-Saharan Africa.^{17,18} These data provide increasing support for efforts to identify and intervene on depression among PLWH, both for the direct health benefits and downstream effects on health-related behaviors, including HIV transmission.

Uganda is a low-income country in sub-Saharan Africa with a generalized HIV epidemic and large expansion of ART services in recent years. The prevalence of depressive symptoms among PLWH in Uganda has been estimated to range from 14–54%, and is notably elevated among HIV-positive women.^{15,19–22} However, few studies have compared rates of depressive symptoms between PLWH and community-based uninfected comparators. One prior study showed that older adults with HIV not on ART may have greater rates of depression than HIV-negative comparators but did not have a sufficient sample size to address the difference between PLWH who are stable on ART and HIV-negative people.²³ Moreover, as HIV treatment programs have expanded, there have been limited data on how ART might contribute to ameliorating depression in this population.²⁴ This study aims to characterize associations between HIV infection, both before and after

ART use, and depressive symptoms in a mixed cohort of aging PLWH and sex and age-matched, population-based, HIV-negative comparators.

METHODS

Data Collection

We used data from the Ugandan Non-Communicable Diseases & Aging Cohort Study

UGANDAC () is an observational cohort study including PLWH in ambulatory HIV care and a group of age and sex-similar uninfected comparators enrolled from the community in the catchment area of the clinic. The design is based on similar mixed cohorts in the US.^{25,26} PLWH were selected using convenience sampling from the Mbarara Regional Referral Hospital Immune Suppression Syndrome (ISS) clinic²⁷. Eligibility criteria for participation included (1) in ambulatory care at the Immune Suppression Syndrome Clinic at Mbarara Regional Referral Hospital, (2) age ≥ 40 years and (3) duration of ART use ≥ 3 years.²⁸ We consecutively selected participants who met these criteria. After enrollment of PLWH, we used a population census of individuals living in the clinic catchment area to select age (by quartile of PLWH participants) and sex-similar HIV-uninfected comparators. HIV-uninfected comparators were recruited from their homes. The study's objective was to test hypotheses related to the impact of HIV on non-communicable diseases, including cardiovascular and pulmonary disease, mental health and geriatric syndromes. Participants are seen annually for NCD data collection. A subset of the PLWH (n=102) were previously enrolled in a study of long-term ART adherence (Uganda AIDS Rural Treatment Outcomes Study [UARTO], funded by U.S. National Institutes of Health R01 MH54907 and P30AI27763). HIV-uninfected, population-based controls were then enrolled from the Nyakabare Parish, a community located about 20 kilometers from the clinic site. This community was within the catchment area for the clinic from which PLWH had been selected. Complete census data were available for this community as part of a related community-based study, enabling random selection of HIV-uninfected comparators similar to PLWH by age (quartile) and sex.²⁹ HIV serostatus was confirmed prior to annual study visits for HIV-uninfected controls. During each study visit, data on demographic, health and socioeconomic characteristics were collected. In addition, for PLWH, HIV viral load (VL), and CD4 + T-cell counts were obtained from the clinical record. In this study, virologic suppression was defined as a VL below the limit of detection of the assay (plasma specimens: < 40 copies/μL; dried blood spots: < 550 copies/μL).²⁷

The outcome of interest in this study is probable depression, as measured by a modified version of the Hopkins Symptom Checklist for Depression (HSCL).³⁰ All participants were administered this scale at their baseline or first follow-up visit. In this study, we use the first available HSCL measurement from the UGANDAC study for each participant. The HSCL is a 15-item scale that quantifies depression symptom severity and has previously been validated in East African populations.^{4,31} Those who score greater than 1.75 on the HSCL are considered to have probable depression. Finally, in a subset of PLWH (n=102), an HSCL score was also available from just before ART initiation, collected during a prior study.²² Among PLWH who were previously enrolled in the long term adherence study, one pre-ART depression score measurement was available, collected on the day of ART initiation.

Statistical Analyses

We first described the cohort by comparing sociodemographic and clinical characteristics between PLWH on ART and HIV-uninfected comparators. We then estimated crude differences in depressive symptoms and prevalence between these two groups by comparing both the difference in the mean HSCL with a student's t-test and the difference in the proportion of participants in each group with an HSCL > 1.75 with a Z-test of proportions. We repeated these estimates comparing PLWH prior to ART with HIV-uninfected individuals, and between PLWH prior to after ART, using a matched pairs analysis for the latter.

We next sought to identify adjusted correlates of probable depression by fitting multivariable log binomial regression models, including HIV status (comparing PLWH on ART and HIV-uninfected comparators), age, sex, educational attainment and household wealth.³²

Household wealth was quantified based on a 21-item series of questions about assets and housing conditions. This summary variable was generated using a principal components analysis and then divided into quartiles to allow within-cohort comparisons of wealth. All statistical analyses were conducted in Stata version 14 (College Station, TX).

Ethics

This study was approved by the Partners Healthcare (2014P001928) and Mbarara University of Science and Technology (06/04–14) human studies ethics committees. All participants gave written informed consent. Participants were informed that both UGANDAC and UARTO were observational cohort studies, and that the questionnaires were not being used for clinical purposes.

RESULTS

The study included 154 PLWH and 142 community-based, HIV-negative controls. There were no differences in mean age, sex, or the prevalence of hypertension or diabetes between HIV-negative participants and PLWH on ART (Table 1). PLWH on ART were more likely to be in the highest wealth quartile by an asset index (13.6 v. 35.1, $p<0.001$). In our sample, PLWH on ART had a mean duration of ART of 8 years, a mean CD4 cell count of 510 and a mean CD4 nadir of 136 (95% CI: 121 – 136). The most common ART regimens were zidovudine, lamivudine and nevirapine (60%), zidovudine, lamivudine, and efavirenz (19%) and tenofovir, lamivudine and efavirenz (8%). Viral load data were available for 94% (145/154) of PLWH on ART; among these, 90% (131/145) were virally suppressed.

PLWH on ART had lower depression symptom scores than HIV-uninfected controls (mean score: 1.50 versus 1.60, $p=0.006$) and a lower prevalence of probable depression (21.4 versus 33.8%, $p=0.017$). The full distribution of HSCL scores in the HIV-negative and PLWH on ART are shown in Figure 1. The distribution of HSCL scores was significantly different for PLWH on ART as compared to the HIV-negative participants in six domains. These included blaming oneself, no desire for sex, difficulty falling asleep, feeling hopeless, feeling unhappy and worrying. In each of these domains, PLWH on ART were more likely to report the absence of symptoms (i.e. “not at all”) over the past seven days, as compared to

their HIV-negative counterparts (blaming oneself: 63% v. 45%, $p=0.011$; no desire for sex: 57% v. 38%, $p<0.001$; difficulty falling asleep 64% v. 47%, $p=0.018$; felt hopeless: 87% v. 73%, $p<0.006$; felt unhappy: 70% v. 52% $p=0.002$; worrying: 66% v. 44%, $p=0.050$). These differences by study group are further detailed in the supplemental appendix (Table S1).

In a sub-analysis of 102 PLWH in whom both pre-ART and post-ART depression screening scores were available, the mean depression score prior to ART was lower in magnitude but not significantly different from the mean score in the HIV-negative group (1.56 v. 1.60, $p=0.5121$). The difference in the mean score between the HIV+ - Pre-ART and HIV+ - Post-ART groups was significant (1.56 v. 1.42, $p=0.035$). The same proportion of participants was depressed in each of these two groups (13%). The mean HSCL and significance testing for all three pairwise comparisons is provided in the supplemental appendix (Table S2).

In unadjusted analyses, PLWH on ART [prevalence ratio (PR): 0.63, 95% CI: 0.43 – 0.94] and those falling in the highest wealth quartile (PR: 0.47, 95% CI: 0.24 – 0.93) had a lower prevalence of probable depression while women had a significantly higher prevalence of probable depression (PR: 1.77, 95% CI: 1.19 – 2.65). These relationships were preserved in multivariable log binomial regression models in which PLWH on ART had a lower prevalence of probable depression than HIV-negative controls [adjusted prevalence ratio (aPR): 0.69 (95% CI: 0.47 – 0.99)]. Those participants in the highest wealth quartile as measured by an asset index had a lower prevalence of probable depression as compared to those in the lowest wealth quartile (aPR: 0.39, 95% CI: 0.18 – 0.87). In addition, women had a higher prevalence of probable depression than men (aPR: 2.02, 95% CI: 1.35 – 3.02). (Table 2)

DISCUSSION

Our study found that PLWH on ART had a lower prevalence of probable depression, as compared to age and sex-matched, population based HIV-negative comparators, after adjustment for key demographic characteristics such as educational attainment and household wealth. Furthermore, depressive symptoms were similar among pre-treatment PLWH and HIV-negative comparators; however, after enrollment in ART care, symptoms of probable depression declined in PLWH. These data add to a growing body of literature demonstrating improved physical and mental health indicators among PLWH on ART in sub-Saharan Africa, compared to people without HIV.³³

The mechanisms responsible for this so-called ‘ART advantage’ require further study, but may include direct effects of ART on HIV replication, inflammation and downstream disease pathophysiology,³⁴ a survivorship bias among those with HIV who link to and remain in care, greater community support and resilience among PLWH who link to care, and positive spillover effects of ART programs in the form of increased access to primary care or psychosocial support services, leading to earlier recognition and management of depression and comorbid health conditions.^{33,35} Longitudinal and qualitative data have also shown that increasing duration of ART is associated with declines in internalized stigma, which could also contribute to the observed declines in depression symptom severity.^{36,37} There may also be a normalization of knowledge of one’s HIV-positive status that

contributes to this decline as well. Alternatively, the benefits of ART might be mediated via reductions in inflammatory pathways that impact depression risk, such as the kynurenine pathway of tryptophan catabolism, which is reduced by use of ART.³⁸ Finally, evidence is emerging from both Uganda and South Africa that there is improved control of other chronic co-morbidities, such as hypertension and diabetes, among people with HIV on ART, compared to uninfected, community based controls in this region.^{33,39}

Our results offer an interesting contrast to recent evidence from high-income countries. For instance, in a study of quality of life of participants in the in the AGEHIV Cohort Study in the Netherlands, PLWH on ART reported significantly worse physical and mental health-related quality of life and had a higher prevalence of depression than HIV-uninfected individuals.⁴⁰ In adjusted models, PLWH on ART had a 1.60 times increased odds of depression compared to HIV-negative participants ($p=0.002$).⁴⁰ In the United States, a similar study showed a prevalence ratio of 2.90 for depression in multivariable adjusted models comparing PLWH on ART to the general population.⁴¹ This may suggest context-specific differences in the drivers of depression – including the role of engagement in HIV care – among those with and without HIV, especially when comparing low- and middle-income settings to high-income settings. Specifically, ART programs may offer a degree of social and health system support that, paradoxically, may advantage PLWH in certain ways compared to the HIV-negative population in LMICs. In contrast, our finding that the mean depression score was significantly lower in PLWH after ART initiation as compared to pre-ART initiation seems to be consistent with findings in high-income settings. For instance, a recent retrospective analysis of data from 281 PLWH initiating ART in the United States showed a significant decrease in depression as measured by the PHQ-9 over the period from just prior to ART initiated to 12 months after ART initiation.⁴²

While the difference between PLWH and HIV-negative participants was a primary focus of this analysis, we also highlight the high prevalence of probable depression in our study population. We find that probable depression is more prevalent than hypertension or diabetes in both PLWH and HIV-negative comparators. This finding reinforces the large burden of depression in sub-Saharan Africa that has been highlighted in other recent epidemiological studies.⁴³ Our finding suggests an urgent need to strengthen diagnostic and therapeutic mental health care services in the region. This finding is also consistent with previous studies that have also demonstrated a need greater investment in mental health services, especially in rural regions.⁴⁴

Secondary findings of this analysis include that women both with and without HIV are twice as likely as men to report depressive symptoms, a finding consistent with prior work in several sub-Saharan African contexts, as well as in studies of sex differences in depression outside this region.^{16,22,45} The drivers of this relationship are poorly understood but important given that depression is in turn associated with other negative health outcomes.¹⁸ Moreover, this study also identified a relationship between wealth and depression, as those who fell into the highest wealth quartile had a significantly lower prevalence of probable depression. The inverse relationship between depression and wealth is one that has been described in the literature previously.^{23,46}

This study should be considered in the context of important limitations. First, we defined probable depression with a screen and not a formal psychiatric evaluation. In studies of PLWH in sub-Saharan Africa, screening instruments tend to over-estimate the prevalence of major depressive disorder by a factor of two to three.⁴ Whereas there is no consensus regarding which of depression scales are optimal to measure depression among PLWH in African settings, we used the HSCL, which has been validated in this population.³¹ In addition, our study was limited to study of PLWH who had survived to the time of presentation to care and completion of at least three years of ART, so should be interpreted as comparing PLWH who are stably in care with uninfected comparators. This study is generalizable to PLWH who have been stable on ART, and should not be taken to represent the global population of PLWH prior to achieving long-term retention in care. Third, we controlled for those confounding factors that were measured in the study and which we hypothesized may be relevant to this analysis. However, it is possible that there are residual, unmeasured confounding factors that we were unable to account for in this analysis and which might partially explain the differences observed between people with and without HIV. Fourth, we did not have longitudinal data in HIV-negative controls to better support a causal framework or exclude the possibility that some members of the cohort had a spontaneous remission of their depression. Finally, this study took place at an HIV clinic and in a region where anti-depressant therapies are not routinely available.

In summary, this study suggests for the first time that PLWH on ART in Uganda might have a lower prevalence of probable depression than a comparable HIV-negative group. Our results add to data about relatively improved health indicators among HIV+ vs HIV- in sub-Saharan Africa. Further research is needed to elucidate the underlying mechanisms for these findings and whether the role of primary care provision for PLWH can be expanded to other chronic diseases in the region.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

This study was funded by the U.S. National Institutes of Health R21 HL124712, P30 AI060354, R24 AG044325, P30 AG024409, MGH Executive Committee on Research, and Friends of a Healthy Uganda. The authors acknowledge the following additional sources of support: K23 MH096620; K23 MH099916.

References

1. Bor J, Herbst AJ, Newell ML, Barnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. *Science*. 22 2013;339(6122):961–965. [PubMed: 23430655]
2. Bloomfield GS, Khazanie P, Morris A, et al. HIV and noncommunicable cardiovascular and pulmonary diseases in low- and middle-income countries in the ART era: what we know and best directions for future research. *J Acquir Immune Defic Syndr*. 9 1 2014;67 Suppl 1:S40–53. [PubMed: 25117960]
3. Bernard C, Dabis F, de Rekeneire N. Prevalence and factors associated with depression in people living with HIV in sub-Saharan Africa: A systematic review and meta-analysis. *PLoS One*. 2017;12(8):e0181960. [PubMed: 28783739]

4. Tsai AC. Reliability and validity of depression assessment among persons with HIV in sub-Saharan Africa: systematic review and meta-analysis. *J Acquir Immune Defic Syndr*. 8 15 2014;66(5):503–511. [PubMed: 24853307]
5. Mendenhall E, Kohrt BA, Norris SA, Ndeti D, Prabhakaran D. Non-communicable disease syndemics: poverty, depression, and diabetes among low-income populations. *Lancet*. 3 04 2017;389(10072):951–963. [PubMed: 28271846]
6. Heestermaans T, Browne JL, Aitken SC, Vervoort SC, Klipstein-Grobusch K. Determinants of adherence to antiretroviral therapy among HIV-positive adults in sub-Saharan Africa: a systematic review. *BMJ Glob Health*. 2016;1(4):e000125.
7. Wroe EB, Hedt-Gauthier BL, Franke MF, Nsanzimana S, Turinimana JB, Drobac P. Depression and patterns of self-reported adherence to antiretroviral therapy in Rwanda. *Int J STD AIDS*. 3 2015;26(4):257–261. [PubMed: 24828554]
8. Seth P, Kidder D, Pals S, et al. Psychosocial functioning and depressive symptoms among HIV-positive persons receiving care and treatment in Kenya, Namibia, and Tanzania. *Prev Sci*. 6 2014;15(3):318–328. [PubMed: 23868419]
9. Byakika-Tusiime J, Crane J, Oyugi JH, et al. Longitudinal antiretroviral adherence in HIV+ Ugandan parents and their children initiating HAART in the MTCT-Plus family treatment model: role of depression in declining adherence over time. *AIDS Behav*. 6 2009;13 Suppl 1:82–91. [PubMed: 19301113]
10. Uthman OA, Magidson JF, Safren SA, Nachega JB. Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis. *Curr HIV/AIDS Rep*. 9 2014;11(3):291–307. [PubMed: 25038748]
11. Bijker R, Jiamsakul A, Kityo C, et al. Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts. *J Int AIDS Soc*. 3 3 2017;20(1):21218. [PubMed: 28362063]
12. Chan BT, Tsai AC. HIV stigma trends in the general population during antiretroviral treatment expansion: analysis of 31 countries in sub-Saharan Africa, 2003–2013. *J Acquir Immune Defic Syndr*. 8 15 2016;72(5):558–564. [PubMed: 27035888]
13. Katz IT, Ryu AE, Onuegbu AG, et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. *J Int AIDS Soc*. 11 13 2013;16(3 Suppl 2):18640. [PubMed: 24242258]
14. Tsai AC. Socioeconomic gradients in internalized stigma among 4,314 persons with HIV in sub-Saharan Africa. *AIDS Behav*. Feb 2015;19(2):270–282.
15. Hatcher AM, Tsai AC, Kumbakumba E, et al. Sexual relationship power and depression among HIV-infected women in Rural Uganda. *PLoS One*. 2012;7(12):e49821. [PubMed: 23300519]
16. Nduna M, Jewkes RK, Dunkle KL, Shai NP, Colman I. Associations between depressive symptoms, sexual behaviour and relationship characteristics: a prospective cohort study of young women and men in the Eastern Cape, South Africa. *J Int AIDS Soc*. 11 15 2010;13:44. [PubMed: 21078150]
17. Lundberg P, Rukundo G, Ashaba S, et al. Poor mental health and sexual risk behaviours in Uganda: a cross-sectional population-based study. *BMC Public Health*. 2 21 2011;11:125. [PubMed: 21338500]
18. Cichowitz C, Maraba N, Hamilton R, Charalambous S, Hoffmann CJ. Depression and alcohol use disorder at antiretroviral therapy initiation led to disengagement from care in South Africa. *PLoS One*. 2017;12(12):e0189820. [PubMed: 29281681]
19. Kaharuzza FM, Bunnell R, Moss S, et al. Depression and CD4 cell count among persons with HIV infection in Uganda. *AIDS Behav*. 7 2006;10(4 Suppl):S105–111. [PubMed: 16802195]
20. Kinyanda E, Weiss HA, Levin J, et al. Incidence and Persistence of Major Depressive Disorder Among People Living with HIV in Uganda. *AIDS Behav*. 6 2017;21(6):1641–1654. [PubMed: 27722834]
21. Nakasujja N, Skolasky RL, Musisi S, et al. Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. *BMC Psychiatry*. 6 10 2010;10:44. [PubMed: 20537129]

22. Tsai AC, Bangsberg DR, Frongillo EA, et al. Food insecurity, depression and the modifying role of social support among people living with HIV/AIDS in rural Uganda. *Soc Sci Med.* 6 2012;74(12): 2012–2019. [PubMed: 22513248]
23. Kinyanda E, Kuteesa M, Scholten F, Mugisha J, Baisley K, Seeley J. Risk of major depressive disorder among older persons living in HIV-endemic central and southwestern Uganda. *AIDS Care.* 12 2016;28(12):1516–1521. [PubMed: 27263868]
24. Chan BT, Tsai AC, Siedner MJ. HIV Treatment Scale-Up and HIV-Related Stigma in Sub-Saharan Africa: A Longitudinal Cross-Country Analysis. *Am J Public Health.* 8 2015;105(8):1581–1587. [PubMed: 26066939]
25. Ginzburg HM, Fleming PL, Miller KD. Selected public health observations derived from Multicenter AIDS Cohort Study. *J Acquir Immune Defic Syndr.* 1988;1(1):2–7. [PubMed: 3063804]
26. Adimora AA, Ramirez C, Benning L, et al. Cohort Profile: The Women's Interagency HIV Study (WIHS). *Int J Epidemiol.* 4 1 2018;47(2):393–394i. [PubMed: 29688497]
27. North CM, Allen JG, Okello S, et al. HIV Infection, Pulmonary Tuberculosis, and COPD in Rural Uganda: A Cross-Sectional Study. *Lung.* 12 19 2017.
28. Siedner MJ, Lankowski A, Tsai AC, et al. GPS-measured distance to clinic, but not self-reported transportation factors, are associated with missed HIV clinic visits in rural Uganda. *AIDS.* 6 1 2013;27(9):1503–1508. [PubMed: 23435294]
29. Global Health Collaborative - MUST Uganda. Global Health Collaborative - MUST Uganda,. 2018; <http://ghcuganda.org/our-work/research-innovation/hopenet/>. Accessed May 30, 2018.
30. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL). A measure of primary symptom dimensions. *Mod Probl Pharmacopsychiatry.* 1974;7(0): 79–110. [PubMed: 4607278]
31. Ashaba S, Kakuhikire B, Vorechovska D, et al. Reliability, Validity, and Factor Structure of the Hopkins Symptom Checklist-25: Population-Based Study of Persons Living with HIV in Rural Uganda. *AIDS Behav.* 6 30 2017.
32. Filmer D, Pritchett LH. Estimating wealth effects without expenditure data--or tears: an application to educational enrollments in states of India. *Demography.* 2 2001;38(1):115–132. [PubMed: 11227840]
33. Manne-Goehler J, Montana L, Gomez-Olive FX, et al. The ART Advantage: Health Care Utilization for Diabetes and Hypertension in Rural South Africa. *J Acquir Immune Defic Syndr.* 8 15 2017;75(5):561–567. [PubMed: 28696346]
34. Norcini Pala A, Steca P, Bagrodia R, et al. Subtypes of depressive symptoms and inflammatory biomarkers: An exploratory study on a sample of HIV-positive patients. *Brain Behav Immun.* 8 2016;56:105–113. [PubMed: 26883521]
35. Bor J, Tanser F, Newell ML, Barnighausen T. In a study of a population cohort in South Africa, HIV patients on antiretrovirals had nearly full recovery of employment. *Health Aff (Millwood).* 7 2012;31(7):1459–1469. [PubMed: 22778335]
36. Tsai AC, Bangsberg DR, Bwana M, et al. How does antiretroviral treatment attenuate the stigma of HIV? Evidence from a cohort study in rural Uganda. *AIDS Behav.* 10 2013;17(8):2725–2731. [PubMed: 23670710]
37. Campbell C, Skovdal M, Madanhire C, Mugurungi O, Gregson S, Nyamukapa C. "We, the AIDS people...": how antiretroviral therapy enables Zimbabweans living with HIV/AIDS to cope with stigma. *Am J Public Health.* 6 2011;101(6):1004–1010. [PubMed: 21164081]
38. Martinez P, Tsai AC, Muzoora C, et al. Reversal of the Kynurenine pathway of tryptophan catabolism may improve depression in ART-treated HIV-infected Ugandans. *J Acquir Immune Defic Syndr.* 4 1 2014;65(4):456–462. [PubMed: 24220289]
39. Feinstein MJ, Kim JH, Bibangambah P, et al. Ideal Cardiovascular Health and Carotid Atherosclerosis in a Mixed Cohort of HIV-Infected and Uninfected Ugandans. *AIDS Res Hum Retroviruses.* 1 2017;33(1):49–56. [PubMed: 27476547]
40. Langebeek N, Kooij KW, Wit FW, et al. Impact of co-morbidity and aging on health-related quality of life in HIV-positive and HIV-negative individuals. *AIDS.* 4 19 2017.

41. Do AN, Rosenberg ES, Sullivan PS, et al. Excess burden of depression among HIV-infected persons receiving medical care in the united states: data from the medical monitoring project and the behavioral risk factor surveillance system. *PLoS One*. 2014;9(3):e92842. [PubMed: 24663122]
42. Eaton EF, Gravett RM, Tamhane AR, Mugavero MJ. Antiretroviral Therapy Initiation and Changes in Self-Reported Depression. *Clin Infect Dis*. 6 15 2017;64(12):1791–1794. [PubMed: 28419238]
43. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. *PLoS Med*. 11 2013;10(11):e1001547. [PubMed: 24223526]
44. Kigozi F, Ssebunnya J, Kizza D, et al. An overview of Uganda's mental health care system: results from an assessment using the world health organization's assessment instrument for mental health systems (WHO-AIMS). *Int J Ment Health Syst*. 1 20 2010;4(1):1. [PubMed: 20180979]
45. Weissman MM, Klerman GL. Sex differences and the epidemiology of depression. *Arch Gen Psychiatry*. 1 1977;34(1):98–111. [PubMed: 319772]
46. Rwakarema M, Premji SS, Nyanza EC, Riziki P, Palacios-Derflingher L. Antenatal depression is associated with pregnancy-related anxiety, partner relations, and wealth in women in Northern Tanzania: a cross-sectional study. *BMC Womens Health*. 9 2 2015;15:68. [PubMed: 26329331]

Figure 1.
Distribution of mean depression screening scores by HIV status in UGANDAC

Figure 2.
Mean HSCL Depression Score among HIV-negative, HIV-positive/Pre-ART and HIV-positive/Post-ART participants in UGANDAC

Table 1.

Demographic & health characteristics of participants in UGANDAC, by HIV status

	HIV-negative	HIV-positive	p
Total	142	154	---
Age (mean)	51.9	52.0	0.854
Female (%)	47.9	47.4	0.934
Asset Index (% in top quartile)	13.6	35.1	<0.001
Depression Screen (Mean + 95% CI)	1.60 (1.54 – 1.67)	1.50 (1.44 – 1.57)	0.036
Depressed (%)	33.8	21.4	0.017
Not happy (%)	17.6	13.0	0.487
Hypertension (%)	25.4	16.9	0.074
Diabetes (%)	2.9	5.2	0.312

Table 2.

Regression analyses of the association between positive baseline depression screen, HIV infection and other key chronic diseases in UGANDAC

	Univariable		Multivariable	
	<i>PR (95% CI)</i>	<i>p-value</i>	<i>aPR (95% CI)</i>	<i>p-value</i>
Age (years)	0.99 (0.98 – 1.02)	0.939	1.01 (0.99 – 1.03)	0.441
Female	1.77 (1.19 – 2.65)	0.005	2.02 (1.35 – 3.03)	0.001
Education				
0–1 Years	REF	REF	REF	REF
2–5 Years	0.77 (0.49 – 1.21)	0.255	0.79 (0.51 – 1.24)	0.313
6+ Years	0.80 (0.51 – 1.25)	0.319	0.76 (0.52 – 1.12)	0.169
Wealth Quartile				
Quartile 1	REF	REF	REF	REF
Quartile 2	0.81 (0.51 – 1.28)	0.362	0.75 (0.48 – 1.16)	0.193
Quartile 3	0.86 (0.55 – 1.34)	0.499	0.87 (0.58 – 1.29)	0.479
Quartile 4	0.47 (0.24 – 0.93)	0.030	0.39 (0.18 – 0.88)	0.023
HIV+	0.63 (0.43 – 0.94)	0.022	0.69 (0.48 – 0.99)	0.049
Diabetes	1.22 (0.56 – 2.67)	0.618	---	---
Hypertension	1.16 (0.76 – 1.76)	0.500	---	---
BMI				
Overweight	0.78 (0.43 – 1.41)	0.417	---	---
Obesity	1.35 (0.86 – 2.10)	0.192	---	---